Is Intelligent Bio Solutions going out of business?

INTELLIGENT BIO SOLUTIONS INC. (INBS) Fundamentals

A quick summary of the latest filed figures while the full analysis loads.

INTELLIGENT BIO SOLUTIONS INC. (INBS) scores 17 out of 100 on fundamentals, Distressed / Caution, based on SEC filing data.

Leading signal: Shares dilution YoY: Reverse split detected; adjusted share change (257.1% YoY) and the capital-structure risk is penalized.

Five questions, kept separate

Survival - Critical

2-3 mo of estimated runway from 2026-06-30, based on $4.0M of cash and short-term investments against $19.5M of annual burn. A disclosed filing event caps this reading; Event Risk carries the detail.

Business quality - Pre-commercial

Operating margins cannot grade a pipeline; Survival and clinical evidence remain the relevant lenses here.

Trajectory - Clinical progress unavailable

Fundamentals can show funding and burn, but not whether the clinical pipeline is advancing.

Valuation - Balanced

32.5% net-cash backing support a balanced pre-commercial Valuation assessment.

Event risk - Critical event risk

Going-Concern Warning is the decisive filing event; one adverse event family is active. Favorable events are shown separately and do not offset adverse risk.

What the rules read

• Shares dilution YoY: Reverse split detected; adjusted share change (257.1% YoY) and the capital-structure risk is penalized.
• FCF margin: -463.16%
• Debt / Equity: -0.39x (Net Cash)
• ROIC: -273.43%
• Filing event risk: Going-Concern Warning (-8 pts)
• Cash Runway (years): 0.20y
• Revenue CAGR (3Y): 49.68%
• Return on Assets: -104.10%
• Cash Burn Deceleration: 66.79% QoQ improvement (Rapid improvement)
• Revenue per Asset Efficiency: 34.43% QoQ (Strong monetization)
• Asset Growth Velocity: 44.75% YoY (Scaling infra)
• Revenue Quality: Quality concerns (DSO +11d, Rev +36%)

Read from filings through 2026-09-02.

Price as of 2026-09-07.